Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Glioma 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Medulloblastoma 7Lung Neoplasms 7Wilms Tumor 6Sarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Neoplasm Metastasis 6Lymphoma, Non-Hodgkin 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Central Nervous System Neoplasms 6Rhabdomyosarcoma 5Lymphoma 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Multiple Myeloma 4Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Sarcoma, Ewing 3Ovarian Neoplasms 3Leukemia, Myeloid, Acute 3Stomach Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2

Interventions

Carboplatin 29Paclitaxel 22Taxes 16Bevacizumab 15Specimen Handling 10Immunoglobulin G 10Disulfides 10Magnetic Resonance Spectroscopy 9Gemcitabine 9Biopsy 9veliparib 8olaparib 8liposomal doxorubicin 7cediranib 6Doxorubicin 6Docetaxel 6Topotecan 5Chemotherapy, Adjuvant 4Oxaliplatin 3Immunohistochemistry 3Gene Expression Profiling 3temsirolimus 2reolysin 2oregovomab 2ipatasertib 2cabozantinib 2berzosertib 2belinostat 2atezolizumab 2aflibercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Fallopian Tube Neoplasms × X-Rays × Clear all
NCT04616534 2025-05-22

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
14 enrolled
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡